

GREENBLUM & BERNSTEIN, P.L.C.
 Intellectual Property Causes
 1941 Roland Clarke Place
 Reston, VA 20191
 (703) 716-1191

Attorney ~~Check~~ No. ~~P21462~~

RECEIVED
 FEB 01 2002
 TECH CENTER 1600/2900

In re application of : Toshiaki TAGAWA et al.

Serial No. : 09/926,154
 (National Stage of PCT/JP00/01563)

Box Non-Fee
 Group Art Unit : 1614
 Examiner : Unknown

I.A. Filed : March 15, 2000

For : LIGAND-BONDED COMPLEX

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is a Second Preliminary Amendment in the above-captioned application.

- ☐ Small Entity Status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously filed.
- ☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- ☒ An Information Disclosure Statement, PTO Form 1449, and references cited.
- ☐ No additional fee is required.

The fee has been calculated as shown below:

Claims After Amendment	No. Claims Previously Paid For	Present Extra	Small Entity		Other Than A Small Entity	
			Rate	Fee	Rate	Fee
Total Claims: 18	*20	0	x 9=	\$	x 18=	\$0.00
Indep. Claims: 1	**3	0	x 42=	\$	x 84=	\$0.00
Multiple Dependent Claims Presented			+140=	\$	+280=	\$0.00
Extension Fees for Month				\$		\$0.00
Total:				\$	Total:	\$0.00

*If less than 20, write 20

**If less than 3, write 3

☐ Please charge my Deposit Account No. 19-0089 in the amount of \$_____.

☒ A Check in the amount of \$_____ to cover the filing/extension fee is included.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-0089.


☒ Any additional filing fees required under 37 C.F.R. 1.16.

☒ Any patent application processing fees under 37 C.F.R. 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136)(a)(3).

Bruce H. Bernstein
 Bruce H. Bernstein
 Reg. No. 29,027

Reg. No. 29,027
 3/1/2002

P21462.A02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshiaki TAGAWA et al.

Serial No : 09/926,154

I.A. Filed : March 15, 2000
(National Stage of PCT/JP00/01563)

For : LIGAND-BONDED COMPLEX

Group Art Unit:1614

Examiner: Unknown

#8
RECEIVED
FEB 01 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
Washington, DC 20231

Sir :

Pursuant to the duty of disclosure set forth in 37 CFR § 1.56 and in accordance with the provisions of 37 CFR §§ 1.97 and 1.98, Applicants hereby bring the following information to the attention of the Examiner:

Enzyme Immunoassay, Eiji Ishikawa et al., Igaku-Shoin, which is cited and discussed in the specification beginning at page 6, first paragraph;

Nuclear Medicine, 31, pp. 473-486 (1994) (with an English language summary), which is cited and discussed in the specification beginning at page 6, first paragraph;

Japanese Patent Unexamined Publication (Kokai) No. 6-157559 (with an English language abstract), which is cited and discussed in the specification beginning at page 8, first paragraph;

P21462.A02

Japanese Patent Unexamined Publication (Kokai) No. 6-220070 (and corresponding English language EP 0 607 978), which is cited and discussed in the specification beginning at page 8, first paragraph;

Liposome, Sunamoto et al., Nankodo, Ch. 2, pp. 21-40, 1998, which is cited and discussed in the specification beginning at page 8, first full paragraph;

Liposome Technology, Vol. 1, 2nd edition, pp. 123-139, which is cited and discussed in the specification beginning at page 8, first full paragraph;

Cancer Research, Vol. 49, 5922-5930 (1989), which is cited and discussed in the specification beginning at page 9, first paragraph;

Biochimica et Biophysica Acta, 455, pp. 269-271 (1976), which is cited and discussed in the specification beginning at page 9, first paragraph;

Advanced Drug Delivery Reviews, Vol. 24, pp. 235-242 (1997), which is cited and discussed in the specification beginning at page 9, first full paragraph;

Japanese Patent Unexamined Publication (Kokai) No. 4-346918 (and corresponding U.S. Patent No. 5,264,221 to Tagawa et al.), which is cited and discussed in the specification beginning at page 9, first full paragraph;

Biochimica et Biophysica Acta, 1070, pp. 246-252 (1991), which is cited and discussed in the specification beginning at page 9, second full paragraph; and

Japanese Patent Unexamined Publication (Kokai) No. 10-263282 (and corresponding EP 0 903 152), which is cited and discussed in the specification beginning at page 9, last full paragraph.

P21462.A02

Further pursuant to the duty of disclosure set forth in 37 CFR § 1.56 and in accordance with the provisions of 37 CFR §§ 1.97 and 1.98, Applicants hereby bring to the attention of the Examiner the International Preliminary Examination Report and the International Search Report issued in connection with counterpart International Application No. PCT/JP00/01563.

Copies of the International Search Report and International Preliminary Examination Report (along with an English language translation thereof) were filed on September 13, 2001 with the present application. The Examiner is referred to the English language translation of the International Search Report and the International Preliminary Examination Report for the relevance indicated by the Japanese Examiner for the cited documents with respect to the claims of the International Application.

Copies of the above-noted publications are enclosed. Each document is listed on the attached PTO-1449 form to permit the Examiner to indicate consideration thereof.


The Examiner is respectfully requested to consider the documents cited above and to confirm such consideration by initialing in the appropriate spaces on the PTO-1449 form and returning a copy of the initialed form to Applicants.

Applicants note that an Office Action on the Merits has not issued in the instant application, and no fee for consideration of this statement is believed to be due. However, if an Office Action on the Merits has issued, and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for consideration of this statement, including any payment under 37 C.F.R. 1.17(p), to be charged to Applicant's Deposit Account No. 19-0089.

P21462.A02

Should there be any questions regarding the above or the present application, the Examiner is invited to contact the undersigned at the below-listed number.

Respectfully submitted,
Toshiaki TAGAWA et al.


Bruce H. Bernstein *Reg. No. 31,296*
Reg. No. 29,027

January 30, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191